Q1 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials Net debt increased by USD 7.9bn mainly due to dividends and share buybacks, partially offset by FCF USDbn -7.2 -7.3 -2.7 Dec 31, 2022 Dividends Treasury share transactions, net 43 Investor Relations | Q1 2023 Results -7.9 -0.1 M&A/Intangible assets transactions, net -0.5 References Abbreviations FINANCIAL PROFILE -15.1 2.7 Free Cash Flow Others Mar 31, 2023 NOVARTIS | Reimagining Medicine

View entire presentation